← Evidence map

ArticleRheumatology (Oxford, England)2020

Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study.

Ryu WatanabePubMed ↗Publisher ↗

No numbers read from the abstract.

2 papers cite it

2020

this papercites it

Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. | OpenQuestion